ARS Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SPRY Nasdaq 2834 ars-pharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ARS Pharmaceuticals, Inc.

Top Growth Companies With Insider Ownership In July 2025 - Jul 1st, 2025 11:35 am
Top Growth Companies With Significant Insider Ownership - Jun 27th, 2025 5:35 am
Top Growth Stocks With Significant Insider Ownership In June 2025 - Jun 24th, 2025 11:35 am
3 Growth Companies With High Insider Ownership And 17% Revenue Growth - Jun 24th, 2025 5:35 am
High Growth Tech Stocks in US for June 2025 - Jun 23rd, 2025 5:38 am
Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Jun 15th, 2025 3:26 am
Top Growth Stocks With Strong Insider Ownership In June 2025 - Jun 12th, 2025 11:35 am
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - May 27th, 2025 6:00 am
Exploring US High Growth Tech Stocks In May 2025 - May 22nd, 2025 5:37 am
What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today - May 15th, 2025 6:04 am
ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ... - May 15th, 2025 1:12 am
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates - May 14th, 2025 6:15 am
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) - May 14th, 2025 5:00 am
ARS Pharma’s epinephrine nasal spray 1mg now available in US - May 8th, 2025 3:06 am
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - May 7th, 2025 6:00 am
ARS Pharmaceuticals And 2 Other Growth Leaders With Insider Ownership - May 6th, 2025 11:35 am
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - May 5th, 2025 6:00 am
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - May 2nd, 2025 6:00 am
US High Growth Tech Stocks To Watch Now - Apr 7th, 2025 5:08 am
ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money - Apr 5th, 2025 3:31 pm